Tech Company Financing Transactions

NextPoint Therapeutics Funding Round

NextPoint Therapeutics closed a $42.5 million Series B funding round on 2/15/2024. Investors included Catalio Capital Management, Arkin Bio-Ventures and Binney Street Capital.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

LabCentral, 238 Main Street, 5th Floor
Cambridge, MA 02142
USA

Phone

Undisclosed

Website

www/nextpointtx.com

Email Address

[email protected]

Overview

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Detlev Biniszkiewicz

        

Chief Medical Officer

Briggs Morrison

        

Chief Scientific Officer

Scott Chappel

        

Browse more venture capital transactions:

Prev: 2/15/2024: Scribe venture capital transaction
Next: 2/15/2024: Simplyblock venture capital transaction

Share this article

Where The Data Comes From

We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary